The ING2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population designed to disrupt the ING2 gene in the A-549 human lung adenocarcinoma cell line. This product provides a heterogeneous pool of gene-edited cells, enabling robust loss-of-function analyses in a physiologically relevant epithelial carcinoma model. The polyclonal format captures a spectrum of editing outcomes, offering a genetically diverse background suitable for studying ING2-dependent phenotypes without clonal selection biases.
The A-549 cell line, derived from a 58-year-old male with lung carcinoma, is an adherent epithelial model widely used for research into non-small cell lung carcinoma (NSCLC). Exhibiting alveolar type II-like characteristics, A-549 cells retain expression of wild-type p53, making them particularly valuable for investigating tumor suppressor pathways and apoptotic mechanisms. Their well-documented genomic and transcriptomic landscape provides a reliable context for examining the functional consequences of ING2 depletion.
ING2 functions as a critical tumor suppressor by enhancing p53 acetylation, thereby potentiating p53 transcriptional activity and promoting cell cycle arrest and apoptosis. ING2 operates within a chromatin-modifying complex that includes mSin3A, HDAC1/2, and SAP30, thereby linking histone deacetylation to transcriptional repression. Upstream regulators such as p53, TGF-beta, and E2F1 modulate ING2 expression, while downstream targets include p21/CDKN1A, BAX, and NF-kB signaling components. Key pathway constituents encompass p53, MDM2, p21/CDKN1A, BAX, HDAC1, mSin3A, and SAP30, anchoring ING2 at the crossroads of DNA repair, apoptosis, and epigenetic regulation.
ING2 downregulation is implicated in lung adenocarcinoma and other malignancies, making this knockout model highly relevant for deciphering tumor-suppressive mechanisms in a lung cancer setting. The A-549 background, with intact p53 signaling, permits detailed analysis of how ING2 loss impacts p53 acetylation, target gene activation, and subsequent apoptosis or growth arrest. This model therefore supports the study of oncogenic progression and the evaluation of therapeutic strategies targeting the p53 pathway or chromatin remodeling complexes.
This ING2 knockout polyclonal cell population is engineered for diverse experimental applications, including tumor suppression research, chromatin remodeling analysis, and drug resistance investigations. Researchers can utilize western blotting and RT-qPCR to quantify expression of downstream effectors such as p21 and BAX, while functional assays??Annexin V staining for apoptosis and MTT for proliferation??enable phenotypic characterization. ChIP-qPCR can map histone modifications at ING2-regulated loci, and p53 reporter assays provide direct measurement of p53 transcriptional activity. Complementary RNA-seq profiling offers transcriptome-wide insights into ING2-dependent gene networks. For further technical details, please contact Ascent Research.
